Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome Inc (IMNM) is a clinical-stage biopharmaceutical company advancing novel antibody therapies for cancer and infectious diseases through its proprietary human memory B cell platform. This page serves as the definitive source for verified corporate announcements, research milestones, and financial disclosures.
Investors and industry professionals will find timely updates on clinical trial progress, strategic collaborations like the Nectin Therapeutics partnership, and regulatory developments. Our curated news collection enables efficient tracking of Immunome's expanding oncology pipeline and infectious disease programs.
Key content categories include therapy development updates, intellectual property announcements, executive leadership changes, and quarterly financial results. All materials are sourced from official company communications and vetted industry reports.
Bookmark this page for streamlined access to Immunome's latest scientific advancements and business developments. For comprehensive analysis of IMNM stock performance, visit Stock Titan's dedicated market data section.
Immunome, Inc. (Nasdaq: IMNM) reported its financial results for Q4 2022, revealing a net loss of $7.8 million, or $0.64 per share, against a total net loss of $36.9 million, or $3.09 per share, for the year. As of December 31, 2022, the company held $20.3 million in cash and equivalents. A noteworthy highlight includes a strategic collaboration with AbbVie, initiating the discovery of up to 10 novel antibody-target pairs, valued at up to $120 million per target. Additionally, preclinical data for its anti-EPN1 antibody showed promising results, indicating a significant tumor volume reduction when combined with existing treatments.
Immunome (Nasdaq: IMNM) announces that Chief Technology Officer Matthew Robinson, Ph.D., will present at the 13th Annual World ADC London conference from March 13-16, 2023. Dr. Robinson's talk on March 15 will focus on Immunome's Discovery Engine, a platform that uses human memory B cells to identify novel therapeutic targets for antibody-drug conjugates (ADCs). This proprietary technology aims to enhance cancer treatments by finding proteins selectively expressed on cancer cells. A copy of the presentation will be available post-event on Immunome's website.
Immunome, Inc. (NASDAQ: IMNM) has established an advisory board featuring Dr. John Lambert and Dr. Anthony Tolcher to enhance the prioritization of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. These treatment modalities are becoming increasingly significant in oncology. Lambert emphasized the importance of identifying next-generation targets for successful ADC and TCR development, while Tolcher noted the growing clinical interest following recent FDA approvals. Immunome's proprietary Discovery Engine continues to uncover potential tumor-selective targets, aiming to broaden therapeutic options for cancer treatments.
Immunome has entered a multi-year collaboration with AbbVie to discover up to 10 novel target-antibody pairs through Immunome’s Discovery Engine. This agreement includes a $30M upfront payment and potential further payments totaling up to $70M for platform access, along with development milestones of up to $120M per target. AbbVie aims to enhance its oncology pipeline with Immunome’s innovative technology, which leverages human memory B cells for effective cancer therapeutics.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
